PDCD4-AS1: A Potential Drug Target and Biomarker (G282997)

Target Name: PDCD4-AS1

NCBI ID: G282997

Other Name(s): PDCD4 antisense RNA 1

PDCD4-AS1: A Potential Drug Target and Biomarker

PDCD4-AS1, also known as PDCD4 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. PDCD4-AS1 is expressed in most tissues and cells, and its levels are regulated by post-transcriptional modification and degradation processes. It is upregulated in a variety of cancers and is closely related to the progression and treatment response of many cancers.

PDCD4-AS1 is a 22nt RNA molecule consisting of an open reading frame (ORF) and an N-terminal tail. ORF includes a protein-coding gene region and an N-terminal non-coding RNA region. The N-terminal noncoding RNA region contains a conserved element consisting of GAGC repeat units found in genes whose expression is upregulated in a variety of cancers.

Expression of PDCD4-AS1 in various cancers

PDCD4-AS1 expression is up-regulated in a variety of cancers, including lung cancer, breast cancer, prostate cancer, and colon cancer. Studies have shown that the expression level of PDCD4-AS1 is closely related to cancer progression and treatment response. Cancer patients with upregulated expression of PDCD4-AS1 usually have poor prognosis, rapid disease progression, and poor response to traditional treatment options.

Pharmacological properties of PDCD4-AS1

PDCD4-AS1 is of high value in drug screening and drug research. First, PDCD4-AS1 can be used for drug target screening. Because PDCD4-AS1 is upregulated in a variety of cancers, it is a potential drug target. In addition, the expression level of PDCD4-AS1 can be used as a biomarker of tumor treatment response.

Clinical application of PDCD4-AS1

As a new biomarker, PDCD4-AS1 has great potential in clinical application in tumor patients. PDCD4-AS1 can be used as a monitoring indicator of tumor treatment response. It can be detected through blood samples to predict the treatment effect of tumor patients. In addition, PDCD4-AS1 can also be used as a predictor of tumor progression. Through the detection of tumor tissue samples, the progression of tumor patients can be predicted.

Biochemical properties of PDCD4-AS1

The biochemical properties of PDCD4-AS1 indicate that it has a high expression level and stability. PDCD4-AS1 can be expressed in a variety of tissue cells, including liver cells, kidney cells, and embryonic cells. In addition, PDCD4-AS1 has good stability in vitro and can be stored for long periods of time and maintain activity after repeated freeze-thaw treatments.

Pharmacokinetic properties of PDCD4-AS1

The pharmacokinetic properties of PDCD4-AS1 indicate that it has rapid clearance and high expression levels. Studies have shown that PDCD4-AS1 is rapidly cleared from the body, with an elimination half-life of less than 1 hour. In addition, the high expression level of PDCD4-AS1 indicates that it has a higher protein content and can accumulate in the body.

Pathological properties of PDCD4-AS1

The expression of PDCD4-AS1 is upregulated in various cancers, indicating that it may be closely related to cancer progression and treatment response. In addition, PDCD4-AS1 can also serve as an important component in tumor tissue and participate in the formation and maintenance of tumor tissue.

Clinical research on PDCD4-AS1

As a new biomarker, PDCD4-AS1 has great potential in clinical application in tumor patients. Currently, some studies have proven that PDCD4-AS1 can be used to predict treatment effects and disease progression in cancer patients. Future research can further explore the role of PDCD4-AS1 in tumor treatment and provide better treatment options for tumor patients.

Protein Name: PDCD4 Antisense RNA 1

More Common Targets